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Phosphodiesterase 5 (PDE5) inhibitors limit myocardial
injury caused by stresses, including doxorubicin chemotherapy.
cGMP binding to PKG I attenuates oxidant-induced disulfide
formation. Because PDE5 inhibition elevates cGMP and pro-
tects from doxorubicin-induced injury, we reasoned that this
may be because it limits PKG I disulfide formation. To inves-
tigate the role of PKG I disulfide dimerization in the develop-
ment of apoptosis, doxorubicin-induced cardiomyopathy was
compared in male wild type (WT) or disulfide-resistant C42S
PKG I knock-in (KI) mice. Echocardiography showed that
doxorubicin treatment caused loss of myocardial tissue and
depressed left ventricular function in WT mice. Doxorubicin
also reduced pro-survival signaling and increased apoptosis in
WT hearts. In contrast, KI mice were markedly resistant to the
dysfunction induced by doxorubicin in WTs. In follow-on
experiments the influence of the PDE5 inhibitor tadalafil on the
development of doxorubicin-induced cardiomyopathy in WT
andKImice was investigated. InWTmice, co-administration of
tadalafil with doxorubicin reduced PKG I oxidation caused by
doxorubicin and also protected against cardiac injury and loss of
function. KI mice were again innately resistant to doxorubi-
cin-induced cardiotoxicity, and therefore tadalafil afforded no
additional protection. Doxorubicin decreased phosphorylation
of RhoA (Ser-188), stimulating its GTPase activity to activate
Rho-associatedproteinkinase (ROCK) inWTs.Thesepro-apopto-
tic events were absent in KI mice and were attenuated inWTs co-
administered tadalafil. PKGIdisulfide formation triggers cardiac
injury, and this initiation of maladaptive signaling can be blocked
by pharmacological therapies that elevate cGMP, which binds
kinase to limit its oxidation.
The anthracycline drug doxorubicin is an effective and fre-
quently used chemotherapeutic in the treatment of cancer. A
major side effect of doxorubicin is cardiotoxicity, leading to
heart failure. This cardiotoxicity occurs acutely within days of
treatment in 11% of cases but also after chronic exposure in
2% of patients (1). Mechanisms proposed to contribute to
doxorubicin cardiotoxicity include oxidative stress, down-
regulation of genes expressing contractile proteins, and apo-
ptosis (2). Doxorubicin-induced cardiomyopathy has poor
prognosis and is frequently fatal; consequently, there is a
need for defining therapies that combat this common side
effect of chemotherapy.
Several animal and human studies showed cGMP analogues
orphosphodiesterase (PDE)2 5 inhibitors,whichpreventhydro-
lysis of cGMP, are protective against doxorubicin-induced car-
diomyopathy without interfering with the efficacy of the treat-
ment (3, 4), although themechanism of this protection remains
incompletely understood. cGMP binds and allosterically acti-
vates cGMP-dependent protein kinase, otherwise known as
protein kinase G (PKG). PKG I comprises a homodimer with
two parallel-aligned monomers held together by a leucine zip-
per (5). PKG I forms a homo interprotein disulfide between
Cys-42 on each of its two chains in response to oxidative stress,
activating the kinase independently of cGMP (6). This disulfide
activation of PKG I in blood vessels induces vasodilation and
blood pressure lowering. Thus, C42S PKG I knock-in (KI)
mice engineered so that they cannot form this disulfide are
resistant to oxidant-induced vasodilation and are basally hyper-
tensive in vivo. Despite living with chronic hypertension, it was
notable that theKImice did not develop cardiac hypertrophy or
progress to heart failure (7). Thismay suggest that expression of
the mutant C42S PKG I in the heart is able to limit the mal-
adaptive changes that normally occur because of the workload
stress imposed on the myocardium by hypertension.
When cGMP binds PKG I, it attenuates oxidant-induced
disulfide formation (8, 9). Because inhibition of PDE5 elevates
cGMP and also provides protection from doxorubicin- or pres-
sure overload-induced injury, we reasoned that this may be
because it limits oxidation of the kinase to the disulfide. Oxida-
tion of PKG I is anticipated during doxorubicin treatment
because it induces oxidative stress through mitochondrial
redox cycling reactions (10). In this scenario disulfide activation
of myocardial PKG Iwould be rationalized to be maladaptive,
explaining why strategies like cGMP elevation are cardiopro-
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tective. Furthermore, the C42S PKG I KI would likely be pro-
tected from doxorubicin-induced injury, in the same way as
they are from hypertension-induced cardiac hypertrophy (7).
Indeed, in this study, we provide evidence that disulfide activa-
tion of PKG I in the heart couples to apoptosis and explains
why therapies that limit oxidation are cardioprotective. Previ-
ous studies have primarily investigated the redox control of
vascular PKG I in terms of blood pressure regulation, whereas
here the focus is the heart, where this kinase is also abundantly
expressed.
Results
Doxorubicin caused dose-dependent PKG I disulfide
dimerization in a primary culture of mouse fibroblasts, freshly
isolated adult rat ventricular myocytes and bovine aorta endo-
thelial cells transfected with WT, but not a C42S PKG I con-
struct. Intraperitoneal injection of doxorubicin into WT mice
induced the acute oxidation of cardiac PKG Imeasured on day
5 after treatment (Fig. 1).
Doxorubicin-induced cardiomyopathywas compared inWT
or C42S PKG I KI mice. Echocardiographic analysis of the
heart showed that treatment ofWTmice with doxorubicin has
adverse effects onmyocardial structure and function. The drug
decreased ejection fraction by 17.1%, reduced left ventricular
mass by 19.1%, lowered aortic valve peak flow by 25.3%, and
attenuated the aortic velocity time integral by 24.7%. Inmarked
contrast KI mice were resistant to this dysfunction induced by
doxorubicin. For example, the ejection fraction was only res-
cued by 0.3%, left ventricular mass by 1.9%, aortic valve peak flow
by 7.2%, and aortic velocity time integral by 5.8% in the KI mice
expressing PKG that cannot be disulfide-activated (Fig. 2A).
This cardioprotection afforded to the KI mouse was associ-
ated with reduction in myocardial tissue apoptosis compared
with WT. Doxorubicin treatment increased myocardial tissue
TUNEL-positive nuclear staining in WT heart from 0.34 
0.04% to 2.35  0.54%. In contrast, doxorubicin did not
increase the number of apoptotic nuclei in KI hearts, whichwas
0.41  0.02% basally and remained similar at 0.44  0.02%
following chemotherapy treatment (Fig. 2B). Consistent with
protection in the KI, the BCL2/Bax ratio, phospho-ERK,
phospho-AKT, and phospho-GSK3 were each significantly
decreased in doxorubicin-treated WT but not C42S PKG trans-
genic hearts subjected to the chemotherapy (Fig. 3).
In a subsequent, separate series of experiments the influence
of PDE3, PDE5, or PDE9 inhibitors on the development of
doxorubicin-induced cardiomyopathy and levels of cyclic
nucleotides (cGMP or cAMP) in WT or KI mice was investi-
gated. The PDE3 inhibitor milrinone did not protect WTmice
from doxorubicin-induced cardiomyopathy and did not alter
cGMP or cAMP levels. The PDE5 long half-life inhibitor tada-
lafil significantly increased cGMP, but not cAMP, in both WT
or KI hearts and protected the WT myocardium from loss of
function. Administration of the PDE9 inhibitor BAY 73-6691
resulted in partial protection of contractile function and a trend
toward increased cardiac cGMP levels (supplemental Table S1).
Based on the findings noted above, the PDE5 inhibitor tada-
lafil was used in subsequent experiments. Co-administration of
tadalafil with doxorubicin reduced the oxidation induced by
acute 4- or 6-h treatmentwith the chemotherapeutic alone (Fig.
4A). Again doxorubicin induced cardiac dysfunction in WT,
lowering ejection fraction and left ventricular mass by 16.5 and
18.2%, respectively. Tadalafil afforded protection against doxo-
rubicin, with only 1.3 and 5.5% losses in ejection fraction and
left ventricular mass, respectively (Fig. 4B). Tadalafil treatment
did not provide protection against doxorubicin-mediated
injury in KI (Fig. 4B), although this was probably because the
chemotherapy alone had little adverse effect on the myocar-
dium of these mice. Similarly, theWT hearts exposed to doxo-
rubicin once again showed enhanced levels of apoptosis as
FIGURE 1.Doxorubicin induced PKG I disulfide dimerization in cells and in the heart. The treatment of primary cultures of mouse fibroblasts (n 3) or
adult rat ventricularmyocytes (n3)with0–10Mdoxorubicin (DOX) induceddose-dependentdisulfidedimerizationof endogenousWTbutnotC42Skinase.
Bovine aortic endothelial cells, which were constitutively deficient in PKG I, were transfected with WT or a C42S kinase (n 3) and showed similar results.
Intraperitoneal injection of doxorubicin into mice induced cardiac PKG I disulfide dimerization (n 12). *, p 0.05 between vehicle and DOX groups.
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indexed by nuclear TUNEL staining (2.56 0.24%). Treatment
of WTs with tadalafil protected their hearts as evidenced by a
lower level of TUNEL staining (1.26  0.29%). The KIs were
again resistant to doxorubicin-induced apoptosis (0.75 
0.07%) compared withWTs; this innate protection was not fur-
ther improved by the co-administration of tadalafil (0.52 
0.04%; Fig. 4C).
Recurrent daily co-treatment with tadalafil limited disulfide
dimerization inWTmouse hearts induced by 5 days of contin-
uous doxorubicin exposure (Fig. 5A). Doxorubicin once again
induced a significant reduction in the BCL2/Bax ratio, phos-
pho-ERK, phospho-AKT, and phospho-GSK3 in WT mouse
hearts. This doxorubicin-induced apoptosis (BCL2/Bax ratio)
and attenuation of pro-survival kinase (phospho-ERK, phos-
pho-AKT, and phospho-GSK3) signaling in WT hearts was
blocked by co-treatment with tadalafil (Fig. 5B). Tadalafil had
little impact on these indices of cell health measured in KI
hearts exposed to doxorubicin, albeit the C42S PKG transgenic
mice had innate resistance to injury caused by doxorubicin
(Figs. 4 and 5). Doxorubicin decreased phospho-RhoA (Ser-
FIGURE 2. Doxorubicin induces apoptosis and reduces heart function in WT but not KI myocardium. A, echocardiographic examination of cardiac function
was performed on WT or KI mice 5 days after doxorubicin (Dox) or vehicle injection. The ejection fraction, left ventricular mass (normalized by tibia length),
aortic valve peak flow, and aortic velocity time integral decreased inWT, but not KI mice, treatedwith doxorubicin (n 4). B, histological assessment of hearts
from WT and KI mice treated with doxorubicin or vehicle (n 4). Hematoxylin and eosin did not show any structural changes. Masson’s Trichrome did not
provide any evidence for collagen formation. TUNEL staining demonstrated a significant increase in the percentage of apoptotic nuclei (red arrows) after
doxorubicin treatment in WT, but not KI hearts (representative image and quantification). Scale bar, 50 m. *, p  0.05 between vehicle and doxorubicin
groups.
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188) levels inWT hearts, which was abrogated by co-treatment
with tadalafil (Fig. 5A). Mirroring these changes, doxorubicin
also increased Rho-associated protein kinase (ROCK) activity
in hearts from WTs exposed to doxorubicin. The phospho-
RhoA Ser-188 levels or ROCK activity was the same in both
genotypes basally, andwas notmodulated inKI following doxo-
rubicin treatment either with or without tadalafil co-adminis-
tration (Fig. 5A).
In vitro kinase assays showed disulfide-activated WT PKG
I, as well as cGMP-activated C42S PKG I that cannot
undergo oxidant-induced activation, phosphorylated histone
H1. Similarly, cGMP-activated C42S PKG I also induced
phosphorylation of RhoA, whereas the disulfide-activated
kinase failed to induce phosphorylation of this target protein
(Fig. 6A). Because oxidant-induced PKG I interprotein disul-
fide formation modulates cGMP-dependent substrate phos-
phorylation (9), the impact of the disulfide bondon the ability of
PKG I to phosphorylate Ser-188 in RhoA was investigated
using an in vitro kinase activity assay. Both oxidized or C42S
mutant PKG I showed dose-dependent activation to cGMP as
assessed by RhoA phosphorylation. However, the disulfide
form of PKG I was less sensitive than the C42S mutant to
cGMP-dependent activation. Thus, the EC50 for cGMP was
0.22  0.07 M for C42S PKG I, whereas the presence of the
disulfide significantly (p  0.05) desensitized the kinase 2.5-
fold to 0.56 0.06 M cGMP (Fig. 6B).
Discussion
The widely expressed PKG I is stimulated by binding of
cGMP, a second messenger that is elevated in cells in response
to NO or natriuretic peptides. PKG I can also be activated
independently of the NO-cGMP pathway by oxidants that
induce interprotein disulfide bond formation (6). cGMP- or
disulfide-activated PKG likely induce different conformations
in the N terminus of PKG I. Because the N-terminal leucine
zipper of the kinase mediates substrate binding, it is probable
that differential targeting occurs depending on the amount of
cGMP or oxidant in the cell. There is likely additional regula-
tory complexity because cGMP or endogenous oxidants can
also be generated at different locations within the cell. Conse-
quently, it is possible that scenario-specific localization of PKG
I occurs depending on the subcellular source of cGMP or oxi-
dant, as well as the amounts of each generated. Indeed, it is
notable that the ability of PKG I to form a disulfide dimer
impacts on its subcellular localization in cardiac myocytes in
response to exogenous hydrogen peroxide or those from
transaortic constriction (TAC)-stressed hearts (11).
The disulfide activation of PKG I is an integral mechanism
of physiological blood pressure regulation under basal condi-
tions. This PKGdisulfide-induced vasodilationmechanismalso
in part mediates nitroglycerin- or hydrogen peroxide disulfide-
induced blood pressure lowering, as well as contributing to sep-
sis-induced hypotension (7, 12–14). In contrast to the vascula-
ture, the role of oxidant-induced disulfide activation of PKG in
the heart is less explored and was the focus of this work.
Although doxorubicin treatment doubles the amount of
PKG I disulfide to modulate downstream signaling, it is nota-
ble that there is also a significant level of oxidation under basal
conditions. If PKG I oxidation limits cell survival, we have to
reconcile this with the basal level present in viable tissue. There
are many pro-survival or pro-apoptotic pathways, with a bal-
ance between them that has the net effect of limiting cell death
in healthy myocardium. We reason that there is probably a
threshold effect, in this case PKG I oxidation, which, when
exceeded, tips the net balance in favor of apoptosis. Such
FIGURE3.Doxorubicindecreasedanti-apoptotic signaling inWTbutnotKI hearts. The expression andphosphorylationof thepro-survival, anti-apoptotic
signaling proteins BCL2, Bax, ERK, AKT, and GSK3were compared in hearts fromWT or KImice treatedwith doxorubicin (Dox) or vehicle. Doxorubicin caused
a general loss in pro-survival signaling in WT cardiac tissue, but the hearts from KI were resistant to this pro-apoptotic event (n 9–12). *, p 0.05 between
vehicle and doxorubicin groups; #, p 0.05 between WT and KI groups.
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threshold-mediated regulatory mechanisms are common in
biological systems.
The role of different PDE isoforms in the development of
cardiomyopathy and apoptosis has beenwidely explored. PDE3
has high affinity for both cAMP and cGMP. However, because
PDE3 only slowly hydrolyzes the cGMP, this competitively
blocks degradation of cAMP; thus, it has been called a “cGMP-
inhibited PDE” (15). Acute PDE3 inhibition increases inotropy
and cardiac output, as well as vasodilation. Thus, PDE3 inhibi-
tors, including milrinone, have been used to treat congestive
heart failure but failed because they increased mortality with
long term therapy (16). One of the potential explanations of the
detrimental effects of chronic PDE3 inhibition is enhanced car-
diomyocyte apoptosis (15). In our experiments milrinone did
not attenuate dysfunction induced by doxorubicin, but it only
increased cAMP levels slightly and insignificantly. The lack of
an effect by milrinone may have differed if an alternant dosing
regimen had been used, especially because it has a half-life of
only2.3 h. PDE9, which is also expressed in the heart, hydro-
lyzes natriuretic-peptide-stimulated cGMP in cardiomyo-
cytes. Its genetic depletion or selective pharmacological inhibi-
tion protects against pressure overload-induced pathological
remodeling and reverses hypertrophy (17). BAY 73-6691, a
selective and potent PDE9 inhibitor, efficiently inhibited this
phosphodiesterase in cells (18). It improved learning andmem-
ory in rats (19) and increased corpus cavernosum relaxation
(20). BAY 73-3391 co-treatment partially protectedWT hearts
from doxorubicin-induced loss of contractile function. How-
ever, although the inhibitor increased the cGMP levels by
50%, this did not reach statistical significance. The short 2-h
half-life of BAY 73-3391 adds complexity when trying to corre-
late cGMP levels with cardioprotection from doxorubicin-in-
duced toxicity.
Previously cGMP-elevating strategies achieved with phar-
macological inhibitors of PDE5 limited cardiac injury caused
by treatment with the anti-cancer drug doxorubicin, which
induces oxidative stress through redox cycling reactions (3,
21–23). Indeed, cells or mice exposed to doxorubicin showed
FIGURE 4. Tadalafil protects WT hearts from doxorubicin-induced injury and dysfunction. A, intraperitoneal injection of doxorubicin (Dox) caused
oxidation of PKG I in mouse hearts 4 or 6 h after treatment (n 3). Tadalafil (Tad) co-treatment significantly decreased the disulfide dimerization induced by
the chemotherapy. B, echocardiographic examination of cardiac functionwas performed onWTor KImice 5 days after doxorubicin or vehicle injectionwith or
without Tadalafil treatment (n 4). The ejection fraction and left ventricular mass (normalized by tibia length) decreased in WT, but not KI mice, treated with
doxorubicin. Co-treatmentwith tadalafil prevented thesemaladaptive changes induced by the chemotherapy.C, a histological assessmentwas carried out on
hearts fromWTor KImice treatedwith doxorubicin or vehicle in thepresence or absence of tadalafil (n 4). TUNEL stainingdemonstrated increased apoptotic
nuclei after doxorubicin treatment inWT, but not KI hearts. Tadalafil treatment prevented the induction of apoptosis inWTbut had little effect on the KI, which
was basally resistant. *, p 0.05 between vehicle and DOX groups; #, p 0.05 between DOX alone and DOX tadalafil groups.
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elevatedPKGdisulfide levels, whichwas attenuated by the pres-
ence of tadalafil. Because tadalafil increases cGMP,we reasoned
that the protective effect of this long half-life PDE5 inhibitor
involved it blocking PKG oxidation to the activated disulfide
state. This was plausible because two independent previous
studies showed that cGMPblocks PKGoxidation (8, 9). Indeed,
this turned out to be the case, with tadalafil limiting increases in
disulfide PKG I occurring during either acute (several hours)
or chronic (5 days) exposure to doxorubicin. This led to the
hypothesis that disulfide bond formation inmyocardial PKG I
may be maladaptive, because it would provide a rational mech-
anistic explanation for the reported ability of tadalafil, and also
sildenafil, to limit doxorubicin-induced injury (3, 21–23).
To further investigate the potential causative role for PKG
oxidation inmyocardial injury, a C42S PKG IKImouse that is
fully resistant to interprotein disulfide formation was com-
pared with littermate WT controls. This involved monitoring
their basal status and subsequent responses to doxorubicin
with or without co-treatment with tadalafil in both genotypes.
The most significant finding was that the KI mouse was highly
resistant to myocardial injury induced by doxorubicin com-
pared with theWT. This protection in the KI was evident from
echocardiographic analysis of heart mass and cardiac function,
as well as histological assessment of apoptosis. Clearly genetic
engineering strategies that prevent, or pharmacological inter-
ventions that limit, PKG I oxidation are cardioprotective. The
protective effect of PDE5 inhibitors, including sildenafil or
tadalafil, has been widely observed in different models of heart
failure (4, 21, 24–26). This protection afforded by cGMP is not
mediated by classical activation of PKG, because the PDE5
FIGURE 5. Tadalafil limits doxorubicin-induced PKG I oxidation and the associated apoptotic signaling in WT, whereas KI are basally protected. A,
PKG I disulfide dimerization, RhoA Ser-188 phosphorylation, RhoA, and ROCK activity in WT or KI hearts treated with doxorubicin (Dox) or vehicle, in the
presence or absence of tadalafil (Tad), was indexed (n  4). This demonstrated that doxorubicin triggered a loss of pro-survival phospho-RhoA (Ser-188)
signaling inWT, and thiswas attenuatedby PDE5 inhibitionwith tadalafil. B, BCL2/Bax ratio, ERK, AKT, andGSK3phosphorylation in hearts fromWTor KImice
treatedwith doxorubicin or vehicle, in the presence or absence of tadalafil, was indexed. Consistent with the loss in anti-apoptotic phospho-RhoA induced by
doxorubicin in WT hearts, there was a concomitant loss of pro-survival signaling in terms of BCL2/Bax ratio, ERK, AKT, and GSK3. *, p 0.05 between vehicle
and DOX groups; #, p 0.05 between DOX alone and DOX tadalafil groups.
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inhibitors were not protective in the C42S PKG I KI, which is
fully responsive to the NO-cGMP pathway (7).These findings
were consistent with oxidative activation of the kinase coupling
to injury, with cGMP elevating strategies being protective sig-
nificantly because they limit PKG I oxidation.
The NO-cGMP-PKG pathway is known to regulate apopto-
sis (27, 28), with cGMP limiting activation of pro-apoptotic
pathways to promote cell survival (29). Consequently, a logical
hypothesis was that the KI was innately protected from doxo-
rubicin toxicity because it was resistant to induction of apopto-
sis, and this could be recapitulated inWTby tadalafil because it
represses the maladaptive pathway triggered by PKG I oxida-
tion. Several lines of evidence suggested that that the myocar-
dium of KImice was highly resistant to apoptosis (TUNEL pos-
itive nuclei) or loss of flux through the ERK, AKT, and GSK3
pro-survival signaling pathways that occurred inWT following
exposure to doxorubicin. This loss or pro-survival kinase sig-
naling and elevated levels of apoptosis induced by doxorubicin
was efficiently blocked by co-administration of tadalafil, further
supporting a causative role for disulfide PKG inmyocardial cell
death during oxidative stress.
We reasoned that there was likely a molecular link between
disulfide PKG and loss of pro-survival signaling and induction
of apoptosis. One of the well established targets of PKG I is
RhoA, amember of the smallGTPase family,members ofwhich
are known for their ability to regulate growth and survival (30).
Indeed, RhoA itselfmediatesmany cell processes including sur-
vival (31, 32), transmitting signals to end effectors by binding
theC terminus of ROCK,which activates it (33). Unfortunately,
we failed to develop a co-immunoprecipitation protocol that
would allow the interaction of PKG Iwith RhoA to be assessed
in tissue under the various experimental conditions. However,
we did demonstrate that disulfide-activated PKG I does not
phosphorylate RhoA in vitro. This was not because the disul-
fide-activated kinase lacked catalytic competency, because this
oxidized form efficiently phosphorylated histone protein. Fur-
thermore, when this disulfide formof PKG Iwas subsequently
incubated with cGMP, it then also induced phosphorylation of
RhoA. Although we found that the interprotein disulfide
decreased the sensitivity of the kinase to cGMP-dependent
activation. Thus, a higher concentration of cGMP is required to
induce the same degree of RhoA phosphorylation achieved by
C42S PKG I, which cannot form the disulfide. Thus, disulfide-
PKG alters its substrate preference, an event that is further
modulated by the cGMP concentration. InWT heart there was
a basal level of phospho-RhoA (Ser-188), which was enhanced
by tadalafil treatment, consistent with an elevation in cGMP
levels that classically activate PKG. In contrast, doxorubicin
treatment that induced disulfide PKG I caused a robust
decrease in phospho-RhoA levels. Thus, it seems that oxidation
of PKG I limits the phosphorylation of RhoA stimulated by the
NO-cGMP pathway that can be potentiated by tadalafil, which
enhances cGMP levels by inhibiting its hydrolysis by PDE5.
This concept is robustly supported by the in vitro studies that
show that interprotein disulfide formation activates the kinase,
although this form of the kinase does not phosphorylate RhoA
unless cGMP is also present. Even when cGMP is present, the
interdisulfide desensitizes the kinase to this classical mode of
activation by the second messenger. These observations are in
line with another study also showing that PKG I interprotein
FIGURE 6. Oxidation of PKG I to the interprotein disulfide state attenuates cGMP-stimulated phosphorylation of Ser-188 RhoA. A, comparison of
phosphorylation of Ser-188 RhoAwith that of Ser-27 histone H1 by recombinant interprotein disulfide dimer or C42S PKG I (n 3). Disulfide dimerization of
PKG I caused its activation and resulted in phosphorylation of histone H1 but not of RhoA. In contrast, cGMP-dependent activation of the kinase resulted in
phosphorylation of both substrates. B, impact of interprotein disulfide formation on the dose-dependent activation and phosphorylation of RhoA by PKG I
(n 4). Oxidation of PKG I attenuated cGMP-dependent activation of the kinase, such that the EC50 for cGMPwas 0.22 0.07M for C42S PKG I, whereas the
presence of the disulfide significantly desensitized the kinase2.5-fold to 0.56 0.06M cGMP. *, p 0.05 between disulfide dimer and C42S PKG I groups.
C, schematic overview of the proposedmechanism by which tadalafil limits cardiac injury otherwise caused by chemotherapy with doxorubicin. Oxidation of
PKG I to its disulfide state triggered by doxorubicin limits its classical activation and interaction with RhoA. This abolishes classical cGMP-PKG I pro-survival
signaling that Rhophosphorylationwouldotherwise stimulate in theabsenceof oxidizedkinase; this potentiates apoptosiswith a consequential loss in cardiac
tissue and function. These observations provide a molecular level rationalization for the cardioprotection PDE5 inhibitors can offer in the setting of failure,
including that commonly triggered by doxorubicin chemotherapy.
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disulfidedesensitizes thekinasetocGMP-dependentphosphor-
ylation of VASP (vasodilator-stimulated phosphoprotein) pro-
tein (9). Because cGMP abrogates disulfide formation in PKG
I (8, 9), we conclude that each mode of activation reciprocally
negatively regulates the alternate mechanism as illustrated in
Fig. 6C.
The phosphorylation of RhoA at Ser-188 negatively regulates
its activity through an enhanced Rho guanine-dissociation
inhibitor interaction (34), and so the reduced phospho-RhoA
levels induced by doxorubicin in WT hearts are anticipated to
stimulate RhoA activity, which it did. This enhanced RhoA
activity should elevate ROCK activity, which it did, an event
tightly associated with myocardial apoptotic injury (35). This
series of events provides an explanation for why doxorubicin
triggers apoptosis inWT but not KImouse heart and why tada-
lafil limits the development of injury. Further credence for this
proposed order of events, which are summarized in Fig. 6C,
comes from studies showing that RhoA binds the N-terminal
leucine zipper of PKG I (36). The importance of the leucine
zipper in the cGMP-dependent binding to RhoAwith PKG I is
demonstrated by subtle alterations to the amphipathic helix
preventing their binding (36). Therefore phosphorylation and
inactivation of RhoA requires cGMP-activated PKG Iwith an
intact leucine zipper (36), which if perturbed in vivo results in
loss of competent kinase function and hypertension (37). These
PKG I zipper mutant mice also have potentiated pathologic
cardiac hypertrophy responses to TAC-induced pressure over-
load compared withWTmice. Furthermore, the zippermutant
mice lacked the sildenafil-mediated protection from TAC
afforded to WT controls (24). Thus, the zipper in PKG I is
integral to the protection that elevation in cGMP by PDE5
inhibitors can provide, and this is because it enables the kinase
to bind and phospho-activate RhoA, which ultimately limits
apoptosis. The C42S PKG IKImice are also innately resistant
to TAC-induced cardiac dysfunction (11). The disulfide in PKG
I occurs between Cys-42 residues directly within the leucine
zipper domain required for targeting of the kinase to RhoA.
This Cys-42 is ideally located to modulate the interaction with
the RhoA GTPase depending on the redox state of the kinase,
with disulfide formation limiting the phosphoactivation and
anti-apoptotic signaling the GTPase would otherwise afford in
the absence of Cys-42 oxidation. Pharmacological inhibition of
PDE5 also protected hair cells from noise-induced cell death
and hearing loss (38), perhaps consistent with disulfide activa-
tion of PKG I being a generic mechanism of cell death in dif-
ferent cell types.
In summary, oxidation of PKG I to its disulfide state trig-
gered by doxorubicin limits its interaction with RhoA. This
abolishes classical cGMP-PKG Ipro-survival signaling, result-
ing in potentiated apoptosis and a consequential loss in cardiac
mass and function. These observations provide a molecular
level rationalization for the broad cardioprotection PDE5
inhibitors can offer, including in the setting of doxorubicin
chemotherapy. Previous studies have primarily focused on the
role of PKG I redox state in the control of vascular tone and
blood pressure, whereas this work highlights an important role
for the oxidation state of this kinase in regulating myocardial
tissue viability during stress.
Experimental Procedures
Animals—All procedures were performed in accordance
with the Home Office Guidance on the Operation of the Ani-
mals (Scientific Procedures) Act 1986 in the United Kingdom
and were approved by the King’s College London Animal Wel-
fare and Ethical Review Body. Mice constitutively expressing
PKG I C42S were generated on a pure C57BL/6 background
by Taconic as described elsewhere (7) with male mice solely
being used in this study. For the assessment of doxorubicin-
induced cardiomyopathy, male WT or C42S PKG I KI age-
and weight-matched littermate mice were randomly assigned
to intraperitoneal saline (0.2 ml) or doxorubicin (Sigma) (15
mg/kg) injection.
In a separate set of experiments, the PDE3 inhibitor milri-
none (sc-201193, Santa Cruz Biotechnology, 0.5 mg/kg in 10%
DMSO), the PDE5 inhibitor tadalafil (14024, Cayman, 1 mg/kg
in 10% DMSO), the PDE9 inhibitor BAY 73-6691 (sc-252407,
Santa Cruz Biotechnology, 1 mg/kg in 10% DMSO), or vehicle
(0.2 ml 10% DMSO in saline) was injected 30 min before doxo-
rubicin on day 0. Thereafter PDE inhibitors were administered
daily, until day 5 when the experiment was terminated. The
mice were culled by intraperitoneal injection of 6.6% sodium
pentobarbitone (200 mg/kg) premixed with heparin (500 USP
units), and tissues were collected for biochemical or histologi-
cal analyses.
Echocardiography—The mice were anesthetized and exam-
ined by echocardiography on day 5 using a high resolutionVevo
770 echocardiography system (VisualSonics) with a RMV-707B
transducer running at 30 MHz. High resolution, two-dimen-
sional B-mode andM-mode images at the level of the papillary
muscles were obtained for offline measurements with Vevo
Software (VisualSonics).
cGMP and cAMP Measurements—Assessment of cGMP or
cAMP content was made with Amersham Biosciences cAMP
(RPN225, GE Healthcare) or cGMP (RPN226, GE Healthcare)
Biotrak Enzyme immunoassay kits following the manufactur-
er’s instructions. Briefly hearts were snap frozen and homog-
enized in cold 6% trichloroacetic acid at 2–8 °C to provide a
10% (w/v) homogenate. Aliquots were centrifuged at 2000
g for 15 min at 4 °C, and the pellet was discarded. The super-
natant was washed 4 times with 5 volumes of water-satu-
rated diethyl ether. The remaining aqueous extract was
lyophilized and then dissolved in the manufacturer’s assay
buffer prior to analysis.
Western Immunoblotting and Rho-ROCK Activity Assays—
Immunoblotting was carried out as before (39), utilizing
maleimide (100 mM) in preparation buffers to alkylate thiols
and limit thiol disulfide exchange. Antibodies used in these
studies included Enzo Life Science PKG (ADI-KAP-PK005),
BDTransductionBCL2 (610538), Sigma phospho-histoneH1.4
(Ser-27) (H7664), Cell Signaling Bax (2774), phospho-AKT
(Ser-473) (9271), AKT (9272), phospho-p44/42 MAPK
(Erk1/2) (Thr-202/Tyr-204) (9101), p44/42 MAPK (Erk1/2)
(9102), phospho-GSK-3/ (Ser-21/9) (9331), GSK-3
(27C10) (9315), Santa Cruz Biotechnology phospho-Rho A
(Ser-188) (sc-32954), HRP-linked secondary antibody (Cell Sig-
naling), and ECL reagent (GE Healthcare) were used. Digitized
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immunoblots were analyzed quantitatively with Gel-Pro Ana-
lyzer 3.1 software.
Rho activity was assessed using a Cell Signaling kit (8820)
according to the manufacturer’s instructions. Measurement of
GTPase activity was based on the ability of GTP-bound (active)
form to bind Rhotekin-RBD fusion protein, which can then be
immunoprecipitated with glutathione resin. The level of acti-
vation was then determined usingWestern blot analysis with a
Rho antibody. ROCK activity was estimated using the ELISA-
basedROCKAssay fromCell Biolabs, following themanufactu-
rer’s protocol.
Generation of Recombinant WT or C42S PKG I—Expres-
sion and purification of WT or mutant PKG I encoded in a
pCDNA3 expression vector was essentially as before (40), but
with some minor protocol alterations. Suspension FreeStyle
293-F cells (R79007, ThermoFisher Scientific) were transfected
with the appropriate PKG I construct using polyethylenei-
mine as a transfection reagent. The cells were harvested by
centrifugation (400  g at room temperature for 15 min) after
72 h. They were then resuspended in ice-cold lysis buffer
comprising 25 mM sodium phosphate buffer, pH 6.8, 10 mM
EDTA, 100 mM NaCl, 10 mM benzamidine hydrochloride, and
10 mM dithiothreitol and then frozen in liquid nitrogen. The
cells were lysed by three freeze-thaw (liquid nitrogen/37 °C)
cycles. The resulting lysate was centrifuged at 140,000 g and
4 °C for 30 min, and the soluble supernatant was loaded onto a
pre-equilibrated 8-(2-aminoethylamino)adenosine-3,5-cyclic
monophosphate column (8-AEA-cAMP agarose; BioLog, Ger-
many), after which the column was washed with 20 column
volumes of lysis buffer and then 5 column volumes of lysis
buffer supplemented with 3 M NaCl. PKG I was then eluted
with lysis buffer supplemented with 150 mM NaCl and 500 M
cAMP, with subsequent extensive dialysis against 25 mM
sodium phosphate buffer, pH 6.8, 2 mM EDTA, and 100
mM NaCl to remove the cAMP. In some protocols, to generate
interprotein disulfideWTPKG I, it was incubatedwith 10mM
lipoic acid for 2 h on ice to obtain 100% oxidized kinase, as
confirmed by SDS-PAGE. Disulfide WT or C42S PKG I was
then underwent size exclusion chromatography on a HiLoad
16/600 Superdex 200-pg column (GE Healthcare) conditioned
with 50 mM sodium phosphate buffer, pH 7.4, and 100 mM
NaCl. Proteins were subsequently concentrated with an Ami-
con Ultra centrifugal filter (Merck Millipore).
In Vitro Kinase Activity Assay—Stoichiometrically oxidized
(to the interprotein disulfide homodimer) or C42S recombi-
nant PKG I (200 ng) was incubated with 800 ng of recombi-
nant RhoA (SRP5127, Sigma) or histone H1 (sc-221729, Santa
Cruz) in 20 l of Omnia Tyr kinase reaction buffer (10 stock,
KB002A, Invitrogen) comprising 20mMTris-HCl, pH7.5, 5mM
MgCl2, 1 mM EGTA, 5 mM -glycerophosphate, 5% glycerol, 1
mM ATP, and 0–10 M cGMP (B1381, Sigma). The reactions
were incubated at 30 °C for 15 min and terminated by addition
of 2 non-reducing SDS sample buffer supplemented with 100
mMmaleimide. Proteins were separated by 4–20% SDS-PAGE,
and phosphorylation of substrates was visualized by Western
immunoblot analysis.
Histology—Myocardium was fixed with 4% formaldehyde,
paraffin-embedded, and sectioned into 5-m slices. Sections
were stained with hematoxylin and eosin. Masson’s trichrome
staining was used to visualize collagen. Apoptosis in the left
ventricle was detected by TUNEL staining using the Cardio-
Tacs staining kit (Trevigen) to generate a dark blue precipitate
in sections. Image capture was performed using Leica DMRB
microscope tiling. Nuclei count was obtained in a blinded fash-
ion with an automated algorithm using Image Pro Plus (Media
Cybernetics).
Statistics—The results are presented as means S.E. Differ-
ences between groups were assessed using one-way analysis of
variance followed by a t test. Differences were considered sig-
nificant at the 95% confidence level.
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the study and wrote the paper. O. P., J. B., and J. S. performed and
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tance and contributed to the preparation of Fig. 2. All authors
reviewed the results and approved the final version of the
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